EBITDA of Bioventus, Inc. Class A – LS:A2APNA
This article displays the EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) for Bioventus, Inc. Class A (LS:A2APNA) on TradingView. It provides financial data for the company, indicating the period, value, and percentage change. The article focuses solely on presenting this financial metric within the TradingView platform.
Bioventus, Inc. Class A Statistics – LS:A2APNA
This page provides financial statistics and ratios for Bioventus, Inc. Class A (LS:A2APNA) on the Lang & Schwarz Tradecenter, including valuation, profitability, liquidity, solvency ratios, and per-share metrics. Users can access annual or quarterly data going back to 2013, though many data points are currently marked as unavailable. The platform offers a hub for investors to analyze the company's financial health and performance.
Cash flow from investing activities of Bioventus, Inc. Class A – LS:A2APNA
This article displays the cash flow from investing activities for Bioventus, Inc. Class A (LS:A2APNA) on TradingView. It appears to be a financial data page rather than a traditional article, providing access to financial information without detailed textual analysis. The content is primarily a listing of navigation and data source acknowledgments.
Bioventus, Inc. Class A Income Statement – LS:A2APNA
This article presents the income statement for Bioventus, Inc. Class A (A2APNA), indicating the total revenue for the last quarter was 114.33 million EUR, a 14.96% decrease from the previous quarter. The net income for Q1 2026 was 2.69 million EUR. The report includes an overview of financial statements, statistics, and dividend information.
Equity in earnings of Bioventus, Inc. Class A – LS:A2APNA
This article provides details on the equity in earnings for Bioventus, Inc. Class A (LS:A2APNA), as listed on the Lang & Schwarz Tradecenter. It indicates that the market is currently closed with no trades recorded. The page includes general market and financial data overview, with core content revolving around the "Equity in earnings" metric for the specified company.
Bioventus, Inc. Class A Dividends – LS:A2APNA
The article provides a financial overview of Bioventus, Inc. Class A (LS:A2APNA) on TradingView. It indicates that the market is currently closed with no trades, and offers information on the company's financials, including dividends, earnings, and revenue.
EBITDA margin % of Bioventus, Inc. Class A – LS:A2APNA
This article focuses on the EBITDA margin percentage of Bioventus, Inc. Class A, identified by the ticker LS:A2APNA on TradingView. It provides financial data for the company under the "Markets" section, specifically for German stocks in Health Technology and Medical Specialties. The page indicates that the market is currently closed with no trades.
CapEx per share of Bioventus, Inc. Class A – LS:A2APNA
The article focuses on the "CapEx per share" metric for Bioventus, Inc. Class A (LS:A2APNA). It appears to be a financial data page from TradingView, providing an overview of the company's capital expenditure per share. The content includes navigation elements common to a financial platform but lacks detailed textual analysis of the metric itself.
Bioventus, Inc. Class A Cash Flow – LS:A2APNA
This article provides key financial data for Bioventus, Inc. Class A (LS:A2APNA), focusing on its cash flow activities. It highlights that the free cash flow for Q1 2026 was €7.24 million, and for the full year 2025, it was €60.80 million with an operating cash flow of €62.98 million. The data is presented annually from 2013 through 2025 for operating, investing, and financing cash flows.
Enterprise value of Bioventus, Inc. Class A – LS:A2APNA
This page provides financial information for Bioventus, Inc. Class A (LS:A2APNA) on TradingView. It indicates that the market is currently closed without any trades. The page specifies that market and reference data are provided by ICE Data Services and FactSet, respectively.
Bioventus, Inc. Class A Revenue Breakdown – LS:A2APNA
This article provides a revenue breakdown for Bioventus, Inc. Class A, trading under the symbol A2APNA on Lang & Schwarz Tradecenter. It highlights that the company generated 483.68 million EUR last year, with Pain Treatments being its highest-performing segment. The United States was the largest contributor to its revenue.
Bioventus, Inc. Class A Earnings and Revenue – LS:A2APNA
Bioventus, Inc. Class A (A2APNA) reported strong financial results for the last quarter, with EPS of 0.13 EUR, significantly exceeding the 0.06 EUR estimate. The company also surpassed revenue expectations, bringing in 114.33 M EUR against an estimated 112.44 M EUR. Analysts are forecasting continued growth for the next quarter, with anticipated EPS of 0.19 EUR and revenue of 136.11 M EUR.
Cost of goods sold of Bioventus, Inc. Class A – LS:A2APNA
The article focuses on the cost of goods sold for Bioventus, Inc. Class A (LS:A2APNA), providing financial data on this specific metric. It indicates that the information is "Made by humans" and sources market data from ICE Data Services and reference data from FactSet.
Pretax income of Bioventus, Inc. Class A – LS:A2APNA
The article focuses on the pretax income of Bioventus, Inc. Class A, identified by its stock symbol LS:A2APNA on the Lang & Schwarz Tradecenter. It indicates that the market is currently closed and no trades have occurred for this stock. The content appears to be a financial data page from TradingView, providing an overview of the company's financial status.
Bioventus, Inc. Class A Revenue Breakdown – DUS:4B8
Bioventus, Inc. Class A (DUS:4B8) generated 483.68 million EUR in revenue last year. The Pain Treatments segment was the top-performing segment, contributing 237.60 million EUR. The United States was the largest regional contributor, accounting for 427.49 million EUR.
Average basic shares outstanding of Bioventus, Inc. Class A – DUS:4B8
This article provides financial data for Bioventus, Inc. Class A (DUS:4B8) on the Dusseldorf Stock Exchange. Specifically, it focuses on the "Average basic shares outstanding" for the company. The content appears to be a stub or a data point from a larger financial platform like TradingView.
Bioventus, Inc. Class A Actuals & Estimates (NASDAQ:BVS)
This article provides an overview of Bioventus Inc. (NASDAQ: BVS) stock, including its current price, historical performance, analyst forecasts, and financial data. It details the company's market capitalization, volatility, recent earnings, revenue figures, and upcoming earnings report date. The article also confirms that BVS does not pay dividends and offers technical analysis ratings.
Price to earnings forward of Bioventus, Inc. Class A – FWB:4B8
The article provides information on the "Price to earnings forward" metric for Bioventus, Inc. Class A (FWB:4B8) on the Frankfurt Stock Exchange. It indicates no current trading activity with the market closed, and the specific value of the metric is listed as "Period Value Change Change % Made by humans" which suggests a placeholder or dynamic content not fully rendered.
Price to earnings forward of Bioventus, Inc. Class A – TRADEGATE:4B8
This article displays the "Price to earnings forward" value for Bioventus, Inc. Class A (4B8) on the Tradegate Exchange. It indicates that the market is closed with no current trades. The data is provided by ICE Data Services and FactSet.
Bioventus, Inc. Class A Actuals & Estimates (FWB:4B8)
This article provides an overview of Bioventus, Inc. Class A (FWB:4B8) stock, including financial actuals and estimates. It addresses frequently asked questions about its stock ticker, price forecasts, historical highs and lows, earnings reports, revenue, net income, dividends, and employee count. The stock forecast indicates a maximum estimate of 13.79 EUR and a minimum of 12.06 EUR.
4B8 Forecast — Price Target — Prediction for 2027
This article provides a forecast for Bioventus, Inc. Class A (4B8) stock, including analyst price targets, historical highs and lows, and financial performance data. It details the company's past earnings and revenue surprises, upcoming earnings dates, and current employee count. The article also confirms that 4B8 does not pay dividends.
Enterprise value to EBITDA forward of Bioventus, Inc. Class A – FWB:4B8
This article provides the enterprise value to EBITDA forward for Bioventus, Inc. Class A (FWB:4B8) on the Frankfurt Stock Exchange. It indicates that the market is currently closed with no trades. The page is part of a financial data service, likely TradingView, offering an overview of the company's financials.
Bioventus, Inc. Class A Trade Ideas — FWB:4B8
This article compiles several trading ideas for Bioventus, Inc. Class A (FWB:4B8, NASDAQ:BVS), highlighting its potential for growth and innovation in the healthcare sector. Analysts point to the company's strong financial performance in Q3 2023, management changes, and strategic contracts for products like DUROLANE® as reasons for optimistic investment outlooks, with some even suggesting a $45 target price. Investors are advised to conduct their own due diligence.
Book value per share of Bioventus, Inc. Class A – FWB:4B8
This article provides access to the book value per share of Bioventus, Inc. Class A, trading on the Frankfurt Stock Exchange under the ticker FWB:4B8. It indicates that the market is closed with no trades. The content also lists various features and services offered by TradingView, the platform on which this information is hosted.
After tax other income/expense of Bioventus, Inc. Class A – TRADEGATE:4B8
This article is a financial data page from TradingView, displaying the "After tax other income/expense" for Bioventus, Inc. Class A (TRADEGATE:4B8). It indicates that the market was closed with no trades showing for the selected period. The page also features standard navigation and copyright information typical of a financial data platform.
Asset turnover of Bioventus, Inc. Class A – TRADEGATE:4B8
This article displays the asset turnover information for Bioventus, Inc. Class A, trading under the symbol 4B8 on the Tradegate Exchange. It indicates that the market was closed with no trades recorded for this particular metric. The content primarily focuses on the financial overview for the company on the TradingView platform.
EBIT per share of Bioventus, Inc. Class A – TRADEGATE:4B8
The article provides financial information for Bioventus, Inc. Class A (TRADEGATE:4B8), specifically focusing on its EBIT per share. It is presented in the context of TradingView's platform, which offers various market data and financial tools. The content highlights the company's stock information and acknowledges the data providers.
Bioventus, Inc. Class A Statistics – TRADEGATE:4B8
This article provides key financial statistics for Bioventus, Inc. Class A (TRADGATE:4B8), including valuation ratios like price-to-sales and enterprise value to EBITDA. It notes the company employed 930 people as of 2025 and presents a detailed breakdown of annual and quarterly metrics, though most specific data points are listed as "—". The content emphasizes various financial ratios, profitability, liquidity, and solvency metrics.
Bioventus, Inc. Class A Trade Ideas — TRADEGATE:4B8
This article compiles several trading ideas for Bioventus, Inc. Class A (4B8 on Tradegate Exchange, BVS on Nasdaq), highlighting its potential for growth and innovation in the medical technologies sector. Traders discuss various strategies, from long positions based on recent financial improvements and strategic partnerships to IPO opportunities. The company's strong management, debt reduction efforts, and contract with Aetna are cited as favorable indicators for investors.
Bioventus (BVS) director receives 25,146 RSUs and converts 32,282 into shares
Bioventus Inc. director Guido J. Neels reported recent equity compensation activity, receiving 25,146 Restricted Stock Units (RSUs) on June 3, 2026. Prior to this, on June 2, 2026, an RSU award of 32,282 units vested and was converted into Class A common stock. Following these transactions, Neels directly holds 117,523 shares of Class A common stock.
BVS SEC Filings - Bioventus Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Bioventus Inc. (BVS) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms. Recent key filings include Nantahala Capital's Schedule 13G/A disclosing a 7.96% stake, Bioventus's entry into a $400 million credit agreement, and FDA 510(k) clearance for its TalisMann and StimTrial Peripheral Nerve Stimulation devices. The platform offers AI-generated summaries, impact scoring, and sentiment analysis for each filing.
Bioventus (BVS) director and 10% owner reports RSU grant and vesting-related share exercise
Bioventus Inc. director and 10% owner John A. Bartholdson reported receiving a grant of 25,146 restricted stock units (RSUs) and exercising 32,282 previously granted RSUs into Class A common stock. These transactions are vesting and compensation-related, not open-market trades. Bartholdson now directly holds 111,902 shares and also has indirect ownership of 6,939,357 shares through Juniper investment entities.
Bioventus (BVS) director Hawkins granted 30,994 RSUs and exercises 39,789 into shares
Bioventus Inc. director William A. Hawkins received a grant of 30,994 Restricted Stock Units (RSUs) on June 3, 2026, which are contingent rights to receive Class A common stock based on continued service. Additionally, 39,789 previously granted RSUs vested and were exercised into 39,789 shares of Class A common stock on June 2, 2026. Following these transactions, Hawkins directly holds 297,640 shares of Class A common stock and 30,994 RSUs as a derivative position.
Bioventus (NASDAQ: BVS) director Sutter awarded 25,146 RSUs and exercises 32,282 shares
Bioventus director Martin P. Sutter was awarded 25,146 Restricted Stock Units (RSUs) on June 3, 2026. Prior to this, on June 2, 2026, he exercised 32,282 RSUs, converting them into Class A common shares. These transactions have increased his direct holdings to 117,523 Class A shares, with additional indirect holdings of over 13 million Class A shares through affiliated investment funds.
Bioventus (BVS) director granted 25,146 RSUs and exercises 32,282 into shares
Bioventus Inc. director Philip G. Cowdy was granted 25,146 Restricted Stock Units (RSUs) which will vest based on his continued board service. Additionally, 32,282 previously awarded RSUs vested and were converted into Class A common shares. These transactions are compensation-related and resulted in Cowdy directly holding 43,982 common shares and having 25,146 RSUs outstanding.
Bioventus (BVS) director exercises RSUs and holds 148,892 shares
Bioventus Inc. director Guy P. Nohra reported equity compensation activity, including the grant of 25,146 restricted stock units (RSUs) and the vesting and exercise of 32,282 RSUs into Class A common stock. Following these transactions, Nohra directly holds 148,892 shares. These movements are routine equity awards and vesting for continued board service, not open-market purchases or sales.
Bioventus (BVS) director granted RSUs and exercises prior awards
Susan M. Stalnecker, a director at Bioventus Inc. (BVS), reported equity compensation activity. On June 3, 2026, she received a grant of 25,146 Restricted Stock Units (RSUs), and on June 2, 2026, 32,282 RSUs vested and were converted into Class A common shares. Following these transactions, she directly holds 138,239 shares of Class A common stock and 25,146 RSUs.
Bioventus (BVS) director Pat Beyer receives 25,146 RSUs and converts 32,282 into Class A shares
Bioventus Inc. director Pat Beyer reported receiving a grant of 25,146 restricted stock units (RSUs) on June 3, 2026. Prior to this, on June 2, 2026, 32,282 previously granted RSUs vested and were converted into Class A common stock. Following these transactions, Pat Beyer directly holds 108,718 Class A common shares and 25,146 outstanding RSUs.
[Form 4] Bioventus Inc. Insider Trading Activity
Mary Kay Ladone, a director at Bioventus Inc. (BVS), reported insider trading activity involving equity compensation. She received a grant of 25,146 Restricted Stock Units (RSUs) on June 3, 2026, and on June 2, 2026, 32,282 previously granted RSUs vested and converted into Class A common shares, increasing her direct holdings to 111,263 shares. No share sales were reported in this Form 4 filing.
Bioventus (BVS) director McMurry-Heath gains shares via RSU vesting and new grant
Bioventus Inc. director Michelle McMurry-Heath reported receiving equity compensation, including the vesting of 32,282 restricted stock units (RSUs) on June 2, 2026, which converted into an equal number of Class A common shares. Subsequently, on June 3, 2026, she was granted an additional 25,146 RSUs. After these transactions, McMurry-Heath directly holds 77,279 shares of Class A common stock.
FDA reclassifies bone growth stimulators; Bioventus says 2026 guidance unchanged
The FDA has reclassified non-invasive bone growth stimulators from Class III to Class II, and new CMS billing rules for these devices will take effect on May 18, 2026. Bioventus, a company in this sector, does not anticipate these changes to materially affect its 2026 financial results and has reiterated its guidance for that year, though it will continue to monitor long-term CMS actions.
CMS reimbursement shifts leave Bioventus (NASDAQ: BVS) 2026 guidance intact
Bioventus Inc. reported that recent FDA reclassification of its Exogen Ultrasound Bone Healing System from Class III to Class II, coupled with updated CMS billing requirements and Medicare fee schedule, will not materially impact its fiscal year 2026 financial results. The company is reiterating its 2026 financial guidance but will continue to evaluate potential longer-term effects of current and future CMS actions. This update was disclosed in an 8-K filing, indicating a neutral near-term sentiment from healthcare regulatory and reimbursement analysts.
BVS SEC Filings - Bioventus Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive overview of Bioventus Inc. (BVS) SEC filings, including 10-K, 10-Q, and 8-K reports, along with insider trading forms. Recent key filings include a 10-Q quarterly report, an 8-K on a $400 million credit agreement, and an 8-K detailing FDA 510(k) clearance for two peripheral nerve stimulation devices. The platform offers AI-generated summaries, impact scoring, and sentiment analysis for each filing.
Statutory Profit Doesn't Reflect How Good Bioventus' (NASDAQ:BVS) Earnings Are
Bioventus Inc.'s recent solid earnings report might have initially underwhelmed investors, but an analysis of its accrual ratio suggests that its financial performance is stronger than statutory profits indicate. The company's free cash flow significantly exceeded its statutory profit, boasting an accrual ratio of -0.15, which is generally considered a positive sign for future profitability. This indicates a robust underlying financial health for Bioventus.
Bioventus reports Q1 revenue $132.1M, adjusted EPS $0.15 and raises cash-flow guidance
Bioventus reported strong first-quarter 2026 results with revenue of $132.1 million, a 7% increase year-over-year, and adjusted diluted earnings per Class A share of $0.15. The company's revenue growth was broad-based across its Pain Treatments, Surgical Solutions, and Restorative Therapies segments. Management also raised its full-year adjusted EPS and cash from operations guidance, while reaffirming its revenue outlook for 2026.
Bioventus (BVS) lifts 2026 EPS outlook after Q1 revenue and cash-flow gains
Bioventus reported strong first-quarter 2026 results, with revenue increasing by 7% to $132.1 million and GAAP diluted EPS turning positive at $0.04. The company significantly improved its cash from operations to $8.9 million from a previous outflow and made a $22.0 million discretionary debt prepayment. Following this performance, Bioventus raised its full-year 2026 guidance for Adjusted EPS and cash from operations while reaffirming net sales projections.
Bioventus (BVS) Q1 EPS Holds Profitability But Tests Bullish Margin Narratives
Bioventus (BVS) reported Q1 2026 revenue of US$132.1 million and basic EPS of US$0.05, maintaining profitability but sparking debate about the durability of its margins. While the company moved from losses a year ago to positive trailing EPS of US$0.43, quarterly net income declined from its Q4 2025 peak, and revenue growth forecasts remain below the broader US market. The stock trades at US$10.92, significantly below its DCF fair value, with a P/E ratio above industry averages, creating tension between its improving earnings and valuation concerns.
[10-Q] Bioventus Inc. Quarterly Earnings Report
Bioventus Inc. reported strong quarterly results, returning to profitability with net sales increasing 6.6% year-over-year to $132.1 million, driven by growth in Pain Treatments and Surgical Solutions. The company achieved a net income of $3.9 million, compared to a $3.3 million loss a year ago, and improved its gross margin to 68.7% and Adjusted EBITDA to $23.9 million. Bioventus also made a discretionary prepayment of $22.0 million on its 2025 Term Loan, signaling a positive financial position and compliance with credit covenants.
Bioventus Inc. 1Q 2026: Revenue $132.09M, EPS $0.04— 10-Q Summary
Bioventus Inc. reported strong first-quarter 2026 results, with revenue increasing to $132.09 million and diluted EPS at $0.04, a significant improvement from a net loss in the prior year. The growth was primarily driven by increased sales volumes in both U.S. and international markets, particularly in pain treatments and ultrasonics. Operational efficiencies and strategic financial actions also contributed to improved gross margin and adjusted EBITDA.
Bioventus Reports First Quarter Financial Results
Bioventus Inc. reported strong first-quarter 2026 financial results, with revenue increasing 7% to $132.1 million. The company delivered GAAP earnings of $0.04 per diluted share and non-GAAP earnings of $0.15 per diluted share, while cash from operations surged by $28.3 million. Bioventus also raised its full-year 2026 guidance for Non-GAAP EPS and Cash from Operations, driven by continued momentum across its core businesses and disciplined execution.
